As noted in new now next in diaTribe #37, Novo Nordisk announced in October 2011 that it had submitted its two new “next-generation” insulin products for approval in the...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
31 readers recommended
On November 28, CeQur announced that it had received CE Mark approval for its PaQ Insulin Delivery Device , allowing the product to be sold in Europe. The Swiss-based...
49 readers recommended
On February 1, the European Commission announced that it had approved Sanofi and Zealand Pharma’s GLP-1 agonist Lyxumia (lixisenatide) for type 2 diabetes. The drug is a...
35 readers recommended
A candid interview with diaTribe advisory board member Dr. Anne Peters touches on the newest drugs and devices, curing type 1, and addressing obesity.
43 readers recommended
This month, in a surprise move, Vivus announced that its weight management medication Qsymia is now available via mail order through Walmart. This is an addition to the...
23 readers recommended
Two well-known endocrinologists debated the merits of inhaled insulin in the February edition of Diabetes Care.
76 readers recommended
A study in the Journal of the American Medical Association ( JAMA ) found that patients with type 2 diabetes who had been taking the GLP-1 agonists Bydureon (exenatide...
38 readers recommended
On September 17, Vivus announced that its obesity medication Qsymia (formerly Qnexa) is now available on the US market – this happened at least several weeks earlier...
95 readers recommended
Why did Qnexa become Qsymia? diaTribe investigates the thinking behind drug names… and why they’re vital to patient safety.
31 readers recommended
Kelly reflects on some changes here at diaTribe and in the world of diabetes and obesity.
36 readers recommended
In March 2013, Novo Nordisk launched Tresiba (insulin degludec) , its new once-daily basal insulin for type 1 and type 2 diabetes, in the UK and Denmark. Tresiba will be...
64 readers recommended
On August 17, the FDA approved Mylan’s new generic versions of Actos (pioglitazone), a once-daily oral tablet for the treatment of type 2 diabetes originally sold by...
24 readers recommended
For World Diabetes Day on November 14, Abbott released a cool new interactive infographic about A Day in the Life of an Insulin-Using Patient . Approximately 26% of the...
42 readers recommended
MannKind’s inhalable ultra-rapid-acting insulin Afrezza has its day at the FDA – find out what it can do for patients and how to speak up!
84 readers recommended
A whole new approach to treating type 2 diabetes at diagnosis, a new type of metformin, and the benefit of adding a GLP-1 agonist to insulin.
51 readers recommended
The three top trends we saw in diabetes in 2013.
41 readers recommended
On March 3, AstraZeneca announced FDA approval for the Bydureon dual-chambered pen (once-weekly exenatide) to improve glycemic control in people with type 2. The device...
51 readers recommended
The Food and Drug Administration (FDA) on March 29, 2013 announced its approval of Janssen Pharmaceuticals' Invokana (canagliflozin), a new SGLT-2 inhibitor for type 2...
29 readers recommended
We ask ACA expert Dr. Jack Lord all the hard questions on healthcare coverage and reimbursement.
23 readers recommended
We travel to Oregon to support test strip access for people with diabetes. Find out what transpired!